Cidara Therapeutics INC. (NASDAQ:CDTX) was established in 2012. It is a biopharmaceutical company that develops new antibodies against fungal infections. It is headquartered in San Diego, California, and has 61 employees.
Cidara Therapeutics (CDTX):
CDTX Biotechnology Company is committed to discovering, developing and commercializing new anti-infective drugs that cannot be solved and dealt with by conventional therapies. The first product of CDTX is CD101 IV, which can be used for the treatment and prevention of systemic fungal infections (through weekly Intravenous injection). The second product is called “CD101 topical”, which can be used for fungal infections of specific parts, such as: vulvovaginal candidiasis, or the treatment of VVC.
In addition, CDTX has developed a unique immunotherapy technology platform, Cloudbreak™, which can use the patient’s immune cells to extract complexes (antibodies) to attack and kill pathogens that cause diseases or infectious diseases. At present, we named the first-generation platform C001, which can be used for the treatment of invasive aspergillosis. To learn more about CDTX’s antibody technology, please pay attention to: company website
Cidara Therapeutics was listed on the Nasdaq in the United States on April 15, 2015, under the stock trading code CDTX, with an issue price of $16, and was jointly underwritten by Jefferies and Leerink Partners. Both CDTX and XBIT are doing research on new antibodies, but they target different fields.